ED
AXSM icon

Exane Derivatives’s Axsome Therapeutics AXSM Stock Holding History

Exane Derivatives’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$87.3K Buy
2,279
+2,249
+7,497% +$71.1K 0.05% 273
2022
Q1 		$1.24K Hold
30
– – ﹤0.01% 791
2021
Q4 		$1.13K Hold
30
– – ﹤0.01% 694
2021
Q3 		$989 Sell
30
-4,417
-99% -$172K ﹤0.01% 865
2021
Q2 		$282K Hold
4,447
– – 0.06% 302
2021
Q1 		$252K Buy
4,447
+189
+4% +$13.3K 0.07% 264
2020
Q4 		$347K Buy
4,258
+3,015
+243% +$225K 0.1% 227
2020
Q3 		$88.6K Sell
1,243
-57
-4% -$4.44K 0.03% 312
2020
Q2 		$107K Hold
1,300
– – 0.03% 282
2020
Q1 		$76.5K Buy
+1,300
New +$106K 0.02% 314

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Exane Derivatives's AXSM Position: Q2 2022 in Review

Exane Derivatives increased its Axsome Therapeutics (AXSM) stake by 7,497% in Q2 2022, buying an estimated $71.1K and bringing the position to 2,279 shares worth $87.3K. The position accounts for 0.05% of the portfolio, ranked #273.

Exane Derivatives first reported a position in AXSM in Q1 2020 and has held it in 10 quarters since. The position peaked at $347K in Q4 2020. 174 funds tracked by Wall St. Rank hold AXSM as of Q2 2022.

  • Exane Derivatives held 2,279 shares of Axsome Therapeutics worth $87.3K as of Q2 2022.
  • Exane Derivatives bought 2,249 Axsome Therapeutics shares in Q2 2022, an estimated $71.1K.
  • Axsome Therapeutics made up 0.05% of Exane Derivatives's portfolio in Q2 2022, its #273 holding.
  • Exane Derivatives first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 10 quarters since.
  • Exane Derivatives's Axsome Therapeutics position peaked at $347K in Q4 2020.
  • 174 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.